ADC	Antibody–drug conjugate
Atezo	Atezolizumab
Ave	Avelumab
BSC	Best supportive care
CI	Confidence interval
CIS	Cisplatin
CR	Complete response
CT	Chemotherapy
Ctr	Control
Durva	Durvalumab
DV	Disitamab vedotin
ECOG PS	Eastern Cooperative Oncology Group performance status
EV	Enfortumab vedotin
Exp	Experimental
Gem	Gemcitabine
ICI	Immune checkpoint inhibitor
Ipi	Ipilimumab
MTS	Metastases
Nivo	Nivolumab
PD-1	Programmed cell death protein 1
PD-L1	Programmed death-ligand 1
Pem	Pembrolizumab
PFS	Progression-free survival
SG	Sacituzumab govitecan
Tori	Toripalimab
Treme	Tremelimumab
UC	Urothelial carcinoma
Unk	Unknown